The company UniQure, which carried the trials of the new method, announced on Wednesday that the rate of development of deadly Huntington's disease slowed down by an average of 75% in several dozen volunteer patients from the United States and Europe, who underwent surgery in 2022 and were then monitored for three years, BBC reports.

The first symptoms of Huntington's disease, as a rule, appear after the age of 30, and the patient usually dies no more than 20 years later.

“It means the decline you would normally expect in one year would take four years after treatment, giving patients decades of ‘good quality life,’" Sarah Tabrizi, professor of clinical neurology and Director of the Huntington's Disease Centre at University College London—and who took part in the trial, told BBC News.